EGFR and non-small cell lung carcinoma: The detection of activating EGFR mutations is nowadays the best predictive marker to treat NSCLC with EGFR-Tyrosine Kinase Inhibitors (TKI)[6], but most trials conducted so far are based on a limited number of known EGFR mutations, including the point mutation at codon 858 of exon 21 (NM_005228.3 p.Leu858Arg) and the numerous in-frame deletions in exon 19, which account for more than 90% of mutations[7].